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emphasizes that further research is needed,
but recommends that the use ofthe additives
should not be abandoned at this time.
The Potential Health Effects ofOxygenates
Added to Gasoline: A Review ofthe Current
Literature was released in April by the
Cambridge, Massachusetts-based Health
Effects Institute, a cooperative effort of the
EPA and the auto industry created to exam-
ine the health effects ofmotor vehicle emis-
sions. HEI conducted a review of existing
research, public complaints, and occupation-
al exposures concerning gasoline additives.
According to the report, potential health
effects from exposure to gasoline containing
MTBE include headaches, nausea, and sen-
sory irritation; acute, reversible neurotoxic
effects (based on studies with rats at high
exposure levels); and cancer (based on
increased frequency of tumors in rats and
mice at high exposure levels). Exposure to
ethanol by ingestion of moderate to large
quantities has been found to increase the risk
ofcancer, adversely affect embryos, and pro-
duce neurotoxicity. However, the report
points out that these effects are unlikely to
occur at low levels ofinhalation.
The report concludes that possible short-
term and cancer-causing effects of exposure
to gasoline without oxygenates are similar to
those from exposure to gasoline with oxy-
genates. Adding oxygenates to gasoline
reduces the emission of carbon monoxide
and benzene from motor vehicles, which
may lower health risks for some people, the
report stated. However, the process may
increase exposure to oxygenates and aldehy-
des, which may have other health risks. The
report concluded that an immediate reduc-
tion in oxygenate use is not warranted at this
time because adding oxygenates is unlikely to
significantly increase health risks associated
with fuel use.
The report recommends that further
research be conducted and outlines several
priorities, including comprehensive assess-
ments of personal exposure to oxygenates,
human environmental chamber studies to
evaluate the health effects of MTBE and
MTBE-gasoline mixtures, epidemiologic and
animal studies to evaluate cancer risks of
MTBE, and comprehensive assessments of
other oxygenates.
The study was commissioned by the
EPA and the Centers for Disease Control
and Prevention (CDC) as part of a broad
review of oxygenated fuels being conducted
by the White House Office of Science and
Technology Policy, which will examine air
quality benefits, engine performance, fuel
economy, and costs of the fuels. The HEI
study's conclusions are similar to those of a
recent National Science and Technology
Council report conducted by an interagency
IARC on Tamoxifen
Tamoxifen, an antiestrogenic compound that has been recognized by the World Health
Organization as an essential drug for the treatment ofbreast cancer, is itselfcarcinogenic,
according to the International Agency for Research on Cancer. IARC researchers, who
met in February in Lyon, France, reviewed evidence on the potential carcinogenicity of
13 pharmaceuticals. Though they found evidence that tamoxifen increases a woman's
risk of developing endometrial cancer, they emphasized that this does not abate the
drug's benefits.
"No woman being treated for breast cancer should have [her] treatment stopped
because of the condusions of the [IARCI working group," the researchers concluded.
"The risk ofendometrial cancer is
far lower than the benefits women
with breast cancer receive from
tamoxifen."
Tamoxifen has been pre-
scribed to women with metastatic
breast cancer for over 20 years and
it is registered for use in nearly
100 countries. It has been used as
both a curative agent and a sec-
ondary cancer-preventive agent,
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and it is also being evaluated for use as a primary preventive agent for healthywomen at
an increased risk ofdeveloping breast cancer, LARC director Paul Kleihues said in a 17
February 1996 artide in TheLancet.
The IARC group, which consisted of 19 scientists from 8 countries, reviewed all the
published scientific data on second primary tumors reported in patients who were given
tamoxifen as treatment for breast cancer. In a draft ofthe study results, the group con-
cluded that there was "sufficient evidence in humans forthe carcinogenicity oftamoxifen
in increasing the risk ofendometrial cancer." However, the group also recognized that
"there is condusive evidence that tamoxifen reduces the risk ofcontralateral breast can-
cers" (second cancers in the other breast), and that "there is inadequate evidence tamox-
ifen affects the riskofothercancers." Theresults ofthestudywill bepublished involume
66 ofthe L4RCMonographs on theEvaluation ofCarcinogenicRisks toHumans.
Though statements on adrug's benefits are not normally induded in the Monographs
series, Kleihues told TheLancetthat the working group would probably make an excep-
tion for tamoxifen. Such a statement may help quell the concerns ofthose worried that
an overzealous reaction to IARC's findings could stop the use ofaverybeneficial medica-
tion. Criticism of the agency's decision to evaluate the carcinogenicity of tamoxifen
began late lastyearwhen thestate ofCalifornia, in response, considered listingtamoxifen
as a carcinogen under its Proposition 65. Critics point out that IARC's report could
cause tamoxifen to bequicklyreplaced byanyofanumberofnewantiestrogens currently
being introduced. With comparatively little human data available on the new drugs, the
danger exists that tamoxifen will be uncritically replaced by a less effective or more toxic
medicine.
Kleihues said that IARC received manyletters concerning its studyon tamoxifen, but
that the agencydid not cancel or reschedule the evaluation as a matter ofprinciple. "It is
important that women have access to scientific opinion on the low risks ofendometrial
cancer," Kleihues and working group chairman George Lucier stated in a press release,
"so thattheycan make informed decisions on the treatmenttheywill accept."
Tamoxifen is one ofthree triphenylethylene antiestrogenic compounds that will be
reviewed in volume 66. The other two, droloxifene, a drug also used in the treatment of
breast cancer, andtoremifene, which isjust beingintroduced, were found to be "not clas-
sifiable" as to theircarcinogenicity to humans dueto inadequate data.
Similar results were found for six ofa group ofseven benzodiazepines and benzodi-
azepine analogues that are used in the treatment ofinsomnia, anxietydisorders, and alco-
holwithdrawal. One, oxazepam, was found to be"possiblycarcinogenic to humans."
Twocholesterol-lowering drugs, dofibrate andgemfibrozil, werealso found to be "not
classifiable" as totheircarcinogenicity to humans. Phenytoin, which is used to treatepilep-
syand certain cardiacarrhythmias, was foundto be"possiblycarcinogenic to humans."
IARC has evaluated the carcinogenicity ofmore than 800 agents. Ofthese, 70 have
been deemed human carcinogens andabout ahalfdozenofthese arestill in use.
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